This is an open label, multi-center study to evaluate the safety and Efficacy of ET-01 Transplantation in subjects with Transfusion Dependent β-Thalassaemia.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Frequency and severity of AEs & SAEs identified according to NCI CTCAE 5.0.
Timeframe: From ET-01 infusion to 104 weeks post-transplant
All-cause mortality
Timeframe: From signing of informed consent to 104 weeks post-transplant
Incidence of transplant-related mortality
Timeframe: Within 100 days post-transplant
Proportion of subjects with engraftment
Timeframe: Up to 42 days post-transplant